Coming of Age for BTK Inhibitor Therapy: A Review of Zanubrutinib in Waldenstrom Macroglobulinemia.

ABSTRACT: Waldenström macroglobulinemia (WM) is a rare form of non-Hodgkin B-cell lymphoma with a variable clinical presentation that can impact a patient's quality of life by causing anemia, peripheral neuropathy, serum hyperviscosity, extramedullary disease, and other symptoms. There are several safe and effective treatment regimens for patients with WM, and the choice of therapy should be made in a personalized fashion considering the patient's symptoms, comorbidities, and genomic profile. Bruton tyrosine kinase (BTK) inhibitors are a new option to treat patients with WM. Zanubrutinib is a next-generation covalent BTK inhibitor designed to have fewer off-target effects than previous BTK inhibitors. This review summarizes the pharmacokinetic and pharmacodynamic properties of zanubrutinib as well a

SUBMITTER: Munoz J 

PROVIDER: S-EPMC9600142 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature